Multifunctional nanosystems: growing sanguinity in siRNA therapy
Authors Badrealam KF, Md Owais M
Received 12 November 2013
Accepted for publication 24 November 2013
Published 10 April 2014 Volume 2014:9(1) Pages 1771—1773
Checked for plagiarism Yes
Khan Farheen Badrealam, Mohammad Owais
Molecular Immunology Laboratory, Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
This letter is in regards to the enlightening work published in the International Journal of Nanomedicine on multifunctional nanosystems developed for surmounting the stumbling blocks of small interfering ribonucleic acid (siRNA) therapeutics.1–4 These published studies make considerable advances toward realizing the great potential of RNA interference (RNAi)-based therapeutics. Despite the curability of the cause of diseases by rectifying altered functionalities of proteins, as of yet no technically viable and safe strategy has been established, owing to their various associated challenges.5 Albeit viral vectors are considered as the most promising strategy, mainly due to their high transduction efficiency and oligonucleotide packaging ability; however their widespread applicability has been marred due to various safety concerns.6 In this regard, nonviral vectors are very attractive, offering a safer alternative, but at a cost of lower transfection efficiency. However, with the advent of next generation nanoparticulate systems, multifunctional nanodelivery systems may bring newer hope to the RNAi therapeutic regimen.
View original paper by Chen and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]